BioNTech SE (22UA.F)
EUR 107.0
(-2.28%)
EUR 107.0
(-2.28%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 3.87 EUR | -90.05% |
| 2022 | 38.08 EUR | -13.2% |
| 2021 | 43.87 EUR | 72773.75% |
| 2020 | 0.06 EUR | 107.08% |
| 2019 | -0.85 EUR | -304.76% |
| 2018 | -0.21 EUR | 44.74% |
| 2017 | -0.38 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -3.42 EUR | -159.09% |
| 2024 Q1 | -1.32 EUR | -170.21% |
| 2023 Q2 | -0.79 EUR | -138.54% |
| 2023 Q4 | 1.88 EUR | 172.46% |
| 2023 FY | - EUR | -90.05% |
| 2023 Q3 | 0.69 EUR | 187.34% |
| 2023 Q1 | 2.05 EUR | -77.07% |
| 2022 Q4 | 8.94 EUR | 28.08% |
| 2022 Q2 | 6.45 EUR | -54.71% |
| 2022 Q1 | 14.24 EUR | 9.96% |
| 2022 FY | - EUR | -13.2% |
| 2022 Q3 | 6.98 EUR | 8.22% |
| 2021 Q3 | 13.14 EUR | 15.06% |
| 2021 Q1 | 4.64 EUR | 201.3% |
| 2021 Q2 | 11.42 EUR | 146.12% |
| 2021 FY | - EUR | 72773.75% |
| 2021 Q4 | 12.95 EUR | -1.45% |
| 2020 FY | - EUR | 107.08% |
| 2020 Q4 | 1.54 EUR | 275.0% |
| 2020 Q3 | -0.88 EUR | -131.58% |
| 2020 Q2 | -0.38 EUR | -58.33% |
| 2020 Q1 | -0.24 EUR | 4.0% |
| 2019 Q1 | -0.18 EUR | -2900.0% |
| 2019 Q3 | -0.13 EUR | 40.91% |
| 2019 Q4 | -0.25 EUR | -92.31% |
| 2019 FY | - EUR | -304.76% |
| 2019 Q2 | -0.22 EUR | -22.22% |
| 2018 Q2 | -0.06 EUR | 0.0% |
| 2018 Q1 | -0.06 EUR | 0.0% |
| 2018 Q3 | -0.10 EUR | -66.67% |
| 2018 Q4 | -0.01 EUR | 94.0% |
| 2018 FY | - EUR | 44.74% |
| 2017 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| CureVac N.V. | -1.18 EUR | 427.966% |
| Biotest Aktiengesellschaft | 3.21 EUR | -20.561% |
| Biotest Aktiengesellschaft | 3.21 EUR | -20.561% |
| BRAIN Biotech AG | -0.38 EUR | 1118.421% |
| Formycon AG | 4.76 EUR | 18.697% |
| Heidelberg Pharma AG | -0.44 EUR | 979.545% |
| Medigene AG | -0.66 EUR | 686.364% |